University of North Carolina Hospitals Pulmonary Disease and Critical Care Medicine

Topics

• Cystic Fibrosis Research Advances 553
• Chronic Obstructive Pulmonary Disease (COPD) Research 113
• Mycobacterium research and diagnosis 107
• Pulmonary Hypertension Research and Treatments 68
• Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 65
• Adenosine and Purinergic Signaling 62
• Neonatal Respiratory Health Research 55
• Air Quality and Health Impacts 51
• Respiratory Support and Mechanisms 51
• Viral Infections and Outbreaks Research 48
• Lung Cancer Diagnosis and Treatment 46
• Asthma and respiratory diseases 42

Most cited

1. Cystic fibrosis.

   Lancet (London, England) · 2021 · 544 citations · Deepika Polineni

2. SARS-CoV-2 infection of the oral cavity and saliva.

   Nature medicine · 2021 · 594 citations · Richard Boucher

3. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.

   American journal of respiratory and critical care medicine · 2022 · 341 citations · Scott H. Donaldson

4. Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

   The Lancet. Respiratory medicine · 2025 · 92 citations · Aaron Trimble

5. Physiology and pathophysiology of human airway mucus.

   Physiological reviews · 2022 · 288 citations · Richard Boucher

6. Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.

   The Lancet. Respiratory medicine · 2025 · 72 citations · Bradley Drummond